Akero Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

Akero Therapeutics zal naar verwachting groeien in winst en omzet met respectievelijk 6.4% en 72.4% per jaar. De winst per aandeel zal naar verwachting groeien met 11.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -186.1% zijn.

Belangrijke informatie

6.4%

Groei van de winst

11.6%

Groei van de winst per aandeel

Biotechs winstgroei	42.4%
Inkomstengroei	72.4%
Toekomstig rendement op eigen vermogen	-186.1%
Dekking van analisten	Good
Laatst bijgewerkt	12 Nov 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

DB:0K4 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	36	-338	-309	-303	4
12/31/2025	N/A	-320	-291	-257	5
12/31/2024	N/A	-265	-189	-161	5
9/30/2024	N/A	-237	-213	-212	N/A
6/30/2024	N/A	-204	-192	-191	N/A
3/31/2024	N/A	-179	-156	-156	N/A
12/31/2023	N/A	-152	-145	-145	N/A
9/30/2023	N/A	-120	-122	-122	N/A
6/30/2023	N/A	-116	-97	-97	N/A
3/31/2023	N/A	-112	-94	-94	N/A
12/31/2022	N/A	-112	-93	-93	N/A
9/30/2022	N/A	-121	-94	-94	N/A
6/30/2022	N/A	-110	-84	-84	N/A
3/31/2022	N/A	-112	-84	-84	N/A
12/31/2021	N/A	-101	-80	-80	N/A
9/30/2021	N/A	-98	-76	-76	N/A
6/30/2021	N/A	-95	-75	-75	N/A
3/31/2021	N/A	-82	-78	-78	N/A
12/31/2020	N/A	-79	-71	-71	N/A
9/30/2020	N/A	-65	-59	-59	N/A
6/30/2020	N/A	-59	-59	-59	N/A
3/31/2020	N/A	-50	-41	-41	N/A
12/31/2019	N/A	-44	-36	-36	N/A
9/30/2019	N/A	-90	-26	-26	N/A
6/30/2019	N/A	-86	-15	-15	N/A
3/31/2019	N/A	-87	-15	-10	N/A
12/31/2018	N/A	-82	-10	-5	N/A
9/30/2018	N/A	-22	-9	-4	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat 0K4 de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat 0K4 de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat 0K4 de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er wordt verwacht dat 0K4 volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat 0K4 volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat 0K4 binnen 3 jaar verliesgevend zal zijn.

Akero Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Akero Therapeutics, Inc. to Showcase New Analyses of Phase 2b Harmony Study in Presentations at 75th Annual AASLD The Liver Meeting®? 2024

Akero Therapeutics, Inc. Provides Business Update

New major risk - Revenue and earnings growth

Insufficient new directors

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

Akero Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Akero Therapeutics, Inc. Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $319 million.

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $319 million.

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

New major risk - Revenue and earnings growth

Akero Therapeutics, Inc. Announces First Patients Dosed in Efruxifermin Phase 3 Synchrony Program

Co-Founder recently sold €404k worth of stock

Akero Therapeutics, Inc. Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins

New minor risk - Share price stability

Akero Therapeutics, Inc. to Present Results from Phase 2B Symmetry Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH

Akero Therapeutics, Inc. Announces Publication of the Harmony Phase 2B Trial Results in the Lancet Gastroenterology & Hepatology

Akero Therapeutics, Inc. to Report Results of Phase 2b SYMMETRY Study in October 2023

Akero Therapeutics, Inc.(NasdaqGS:AKRO) dropped from Russell Small Cap Comp Value Index

Co-Founder & Chief Scientific Officer recently sold €1.9m worth of stock

Akero Therapeutics, Inc. Releases Topline Data from an Expansion Cohort of the Phase 2B SYMMETRY Study

Akero Therapeutics, Inc. Announces the Appointment of Patrick Lamy as Senior Vice President, Commercial Strategy

Akero Therapeutics, Inc. Completes Enrollment of Phase 2B SYMMETRY Study

Independent Director recently sold €1.1m worth of stock

Independent Director recently sold €12m worth of stock

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Akero Therapeutics, Inc. Releases Topline Data from HARMONY

Akero Therapeutics, Inc. Announces Results from Cohort C of its Phase 2a BALANCED trial in non-alcoholic steatohepatitis

Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis

Akero Therapeutics, Inc. announced that it expects to receive $100 million in funding from Hercules Capital, Inc.

High number of new directors

High number of new directors

Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients

Akero Therapeutics Presents at the American Diabetes Association’s 81st Scientific Sessions, Demonstrating that Improvements in Adipose Tissue Metabolism Contributed Substantially to Improved Liver Health and Better Glycemic Control in Efruxifermin (EFX)-treated Pre-Cirrhotic NASH Patients

New 90-day high: €27.80

Akero Therapeutics, Inc. Initiates Phase 2B Harmony Study of Efruxifermin (Efx) for the Treatment of NASH

New 90-day high: €27.00

New 90-day high: €25.00

New 90-day low: €20.20

New 90-day low: €20.60

Akero Therapeutics, Inc. Presents Additional Positive Data from Phase 2a BALANCED Study Demonstrating Potential of Efruxifermin as a Foundational NASH Monotherapy

New 90-day low: €23.80

Akero Therapeutics Completes Enrollment of Cohort of Cirrhotic (F4) Patients in Ongoing Balanced Study

Akero Therapeutics to Present Data from Phase 2a BALANCED Study Of Efruxifermin In NASH Patients In Presidential Plenary Talk at The Liver Meeting® 2020

New 90-day low: €26.20

Akero Therapeutics To Continue Efruxifermin Development With Innovative Adaptive Phase 2b/3 Clinical Trial Design Based On FDA Written Guidance

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $188.213976 million.

Akero Therapeutics, Inc.(NasdaqGS:AKRO) dropped from Russell Microcap Value Index

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven